Dermapose™ is the newest cutting-edge fat transfer technology from Puregraft dedicated to volumization and rejuvenation.
Dermapose Refresh is a unique all-in-one-tool design to purify, microsize and reinject a patient’s own fat.
This sterile and single use syringe allows doctors to reinject ~15cc of microfat.
The 50 mL vacuum-lock syringe with a built-in 800 μm filter designed to gently microsize adipose tissue parcel size allows for easier injection through small 18-21G injectors.
For optimum performance, Dermapose Refresh should be used in conjunction with the Dermapose Refresh Stand, which is a reusable, autoclavable component designed to hold the syringe securely during use.
30cc Output Syringe
Microfat sized to less than 800µm
and collected in a closed system
prior to transfer to injection syringes
(twist to remove)
Built in Vacuum Lock
Designed to hold vacuum pressure
during harvesting (lock at full vacuum)
50cc chamber with built-in dead space
Allows harvesting of up to 50cc lipoaspirate. Dead space ensures syringe vacuum pressures do not exceed 25 inHg
800 μm Sizing Filter
Single step sizing filter used to separate microfat (>800um) in sterile manner allowing injection through 21G cannula
Luer lock cannula hub
Luer lock hub designed to work with included cannula set
14G x 15cm infiltration/harvesting cannula
Infiltrate and harvest lipoaspirate using the included 14G cannula
We have also developed a guided harvesting aid that integrates seamlessly with Dermapose Refresh.Discover Dermapose Access
Dermapose™ harnesses the regenerative power of fat to reshape and rejuvenate. Stem cells, preadipocytes and mature fat cells are found in abundance within every microfat transfer.
Unlike temporary fillers, which are typically absorbed by the body within 6 months, Dermapose™ uses the patient´s own microfat to address volume loss in the face with long-lasting results that range from 8 to 12 years.
Several market research reveal a high potential of the fat transfer procedure used for aesthetic purposes.
performed in 2016 in the U.S. (5)
with a share of around 50% in 2018. (6)
Minimally invasive & non-invasive treatment is a significant factor estimated to stimulate market growth.